Literature DB >> 31570491

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

Joshua N Gustine1,2, Lian Xu1, Nicholas Tsakmaklis1, Maria G Demos1, Amanda Kofides1, Jiaji G Chen1, Xia Liu1, Manit Munshi1, Maria Luisa Guerrera1, Gloria G Chan1, Christopher J Patterson1, Andrew Keezer1, Kirsten Meid1, Toni Dubeau1, Guang Yang1,3, Zachary R Hunter1,3, Steven P Treon1,3, Jorge J Castillo1,3.   

Abstract

Entities:  

Keywords:  CXCR4; Lymphomas and Other Lymphoproliferative Conditions; MYD88; NEOPLASIA; Waldenström macroglobulinemia; ibrutinib

Mesh：

Substances：

Year:  2019        PMID： 31570491      PMCID： PMC6784519          DOI： 10.1182/bloodadvances.2019000635

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  19 in total

Review 1.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Roger G Owen; Steven P Treon; Ayad Al-Katib; Rafael Fonseca; Philip R Greipp; Mary L McMaster; Enrica Morra; Gerassimos A Pangalis; Jesus F San Miguel; Andrew R Branagan; Meletios A Dimopoulos
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

2.  MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Zachary Hunter
Journal:  N Engl J Med       Date:  2015-08-06       Impact factor: 91.245

3.  The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Robert J Manning; Christina Tripsas; Christopher J Patterson; Patricia Sheehy; Steven P Treon
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

4.  SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.

Authors:  Hai T Ngo; Xavier Leleu; Jack Lee; Xiaoying Jia; Molly Melhem; Judith Runnels; Anne-Sophie Moreau; Nicholas Burwick; Abdel Kareem Azab; Aldo Roccaro; Feda Azab; Antonio Sacco; Mena Farag; Robert Sackstein; Irene M Ghobrial
Journal:  Blood       Date:  2008-04-30       Impact factor: 22.113

5.  Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Nickolas Tsakmaklis; Maria G Demos; Amanda Kofides; Cristina Jimenez; Gloria G Chan; Jiaji Chen; Xia Liu; Manit Munshi; Joshua Gustine; Kirsten Meid; Christopher J Patterson; Guang Yang; Toni Dubeau; Mehmet K Samur; Jorge J Castillo; Kenneth C Anderson; Nikhil C Munshi; Steven P Treon
Journal:  Blood Adv       Date:  2018-11-13

6.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

7.  C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.

Authors:  Aldo M Roccaro; Antonio Sacco; Cristina Jimenez; Patricia Maiso; Michele Moschetta; Yuji Mishima; Yosra Aljawai; Ilyas Sahin; Michelle Kuhne; Pina Cardarelli; Lewis Cohen; Jesus F San Miguel; Ramon Garcia-Sanz; Irene M Ghobrial
Journal:  Blood       Date:  2014-04-07       Impact factor: 22.113

8.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Authors:  Lian Xu; Zachary R Hunter; Guang Yang; Yangsheng Zhou; Yang Cao; Xia Liu; Enrica Morra; Alessandra Trojani; Antonino Greco; Luca Arcaini; Marzia Varettoni; Maria Varettoni; Jennifer R Brown; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi; Christopher J Patterson; Robert J Manning; Christina K Tripsas; Neal I Lindeman; Steven P Treon
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

9.  Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.

Authors:  Steven P Treon; Yang Cao; Lian Xu; Guang Yang; Xia Liu; Zachary R Hunter
Journal:  Blood       Date:  2014-02-19       Impact factor: 22.113

10.  The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.

Authors:  Y Cao; Z R Hunter; X Liu; L Xu; G Yang; J Chen; C J Patterson; N Tsakmaklis; S Kanan; S Rodig; J J Castillo; S P Treon
Journal:  Leukemia       Date:  2014-06-10       Impact factor: 11.528
View more
  10 in total

Review 1.  Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.

Authors:  Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

2.  Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.

Authors:  Jorge J Castillo; Kirsten Meid; Catherine A Flynn; Jiaji Chen; Maria G Demos; Maria L Guerrera; Amanda Kofides; Xia Liu; Manit Munshi; Nicholas Tsakmaklis; Christopher J Patterson; Guang Yang; Zachary Hunter; Steven P Treon
Journal:  Blood Adv       Date:  2020-08-25

3.  Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response.

Authors:  Nagham Alouche; Amélie Bonaud; Vincent Rondeau; Rim Hussein-Agha; Julie Nguyen; Valeria Bisio; Mélanie Khamyath; Etienne Crickx; Niclas Setterblad; Nicolas Dulphy; Matthieu Mahevas; David H McDermott; Philip M Murphy; Karl Balabanian; Marion Espéli
Journal:  Blood       Date:  2021-06-03       Impact factor: 25.476

4.  Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia.

Authors:  Joshua N Gustine; Lian Xu; Guang Yang; Xia Liu; Amanda Kofides; Nicholas Tsakmaklis; Manit Munshi; Maria Demos; Maria L Guerrera; Kirsten Meid; Christopher J Patterson; Shayna Sarosiek; Andrew R Branagan; Zachary R Hunter; Jorge J Castillo; Steven P Treon
Journal:  Br J Haematol       Date:  2021-03-13       Impact factor: 8.615

5.  Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials.

Authors:  Jorge J Castillo; Joshua N Gustine; Kirsten Meid; Catherine A Flynn; Maria G Demos; Maria L Guerrera; Cristina Jimenez; Amanda Kofides; Xia Liu; Manit Munshi; Nicholas Tsakmaklis; Christopher J Patterson; Lian Xu; Guang Yang; Zachary R Hunter; Steven P Treon
Journal:  Hemasphere       Date:  2020-05-21

6.  [Clinical characteristics and prognosis of Waldenström's macroglobulinemia: a clinical data report from a single center].

Authors:  Y C Jia; J Lu; W T Qiang; L Li; J Liu; H Jiang; W J Fu; J Du
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-12-14

Review 7.  Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.

Authors:  Francesco Piazza; Veronica Di Paolo; Greta Scapinello; Sabrina Manni; Livio Trentin; Luigi Quintieri
Journal:  Front Oncol       Date:  2022-01-11       Impact factor: 6.244

8.  Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.

Authors:  Jorge J Castillo; Jithma P Abeykoon; Joshua N Gustine; Saurabh Zanwar; Kirsten Mein; Catherine A Flynn; Maria G Demos; Maria L Guerrera; Amanda Kofides; Xia Liu; Manit Munshi; Nickolas Tsakmaklis; Rebecca King; Guang Yang; Zachary R Hunter; Ranjana H Advani; Maria Lia Palomba; Stephen M Ansell; Morie A Gertz; Prashant Kapoor; Steven P Treon
Journal:  Br J Haematol       Date:  2020-11-18       Impact factor: 6.998

Review 9.  Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom's Macroglobulinemia.

Authors:  Samantha Milanesi; Massimo Locati; Elena Monica Borroni
Journal:  Int J Mol Sci       Date:  2020-08-08       Impact factor: 5.923

10.  Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.

Authors:  Joshua N Gustine; Shayna Sarosiek; Catherine A Flynn; Kirsten Meid; Carly Leventoff; Timothy White; Maria Luisa Guerrera; Lian Xu; Amanda Kofides; Nicholas Tsakmaklis; Manit Munshi; Maria Demos; Christopher J Patterson; Xia Liu; Guang Yang; Zachary R Hunter; Andrew R Branagan; Steven P Treon; Jorge J Castillo
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 11.047
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.